Brain-derived neurotrophic factor among patients with alcoholism

Martín-González, Candelaria; Romero-Acevedo, Lucía; Fernández-Rodríguez, Camino; Medina-Vega, L.; García-Rodríguez, Alen; Ortega-Toledo, Paula; González-Navarrete, Lourdes; Vera-Delgado, Víctor Eugenio; González‐Reimers, Emilio

doi:10.1017/s1092852920001431

Cited by 10 publications

(3 citation statements)

References 45 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, one of the most recent studies showed that chronic alcoholism was not associated with changes in central BDNF, i.e. brain atrophy, but rather a measure of BDNF expressed in peripheral tissue 94 . Therefore, the inverse association between BDNF and alcohol consumption previously noticed could be due to other underlying factors, such as depression 95 .…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

The association between levels of brain‐derived neurotrophic factor and comorbid depression in patients with cardiovascular disease: The Framingham Heart Study

Medved,

Salinas,

Kojis

et al. 2024

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

AimThe current study aims to investigate the association of serum brain‐derived neurotrophic factor (BDNF) levels with symptoms of depression in adults with and without prevalent cardiovascular disease (CVD), an often burdensome comorbidity.MethodsThis cross‐sectional study included participants from FHS (Framingham Heart Study) who had available serum BDNF levels. Depressive symptoms were assessed using the Center for Epidemiological Studies–Depression Scale (CES‐D) with a score ≥16 indicating mild to moderate and ≥21 severe depression. Participants taking antidepressant medications were excluded from the study.ResultsAltogether 3716 FHS participants were included in the final analysis (mean age, 64.3 ± 11.5 years; 55% women). After adjusting for potential confounders, greater BDNF levels were associated with reduced severe depression risk (odds ratio [OR], 0.78 [95% CI, 0.64–0.96]; P = 0.016). Among participants with CVD, greater BDNF levels were related to lower risk of depressive symptoms (CES‐D ≥ 16 OR, 0.63 [95% CI, 0.45–0.89], P = 0.008; CES‐D ≥ 21 OR, 0.49 [95% CI, 0.31–0.76], P = 0.002). The inverse relationship between BDNF and depressive symptom risk was present in women with CVD (CES‐D ≥ 16 OR, 0.63 [95% CI, 0.40–0.99], P = 0.047; CES‐D ≥ 21 OR, 0.38 [95% CI, 0.21–0.70], P = 0.002) but not in men.ConclusionLower serum BDNF levels are associated with a higher risk of depressive symptoms in CVD, particularly among women. These findings implicate BDNF in the complex biological mechanisms that underlie prior associations observed between CVD and depression. To reduce the burden of depression in the large proportion of midlife and older adults with CVD, a better understanding of how BDNF may modify these pathways is merited.

show abstract

Section: Discussionmentioning

confidence: 95%

“…brain atrophy, but rather a measure of BDNF expressed in peripheral tissue. 94 Therefore, the inverse association between BDNF and alcohol consumption previously noticed could be due to other underlying factors, such as depression. 95 Dietary patterns and foods could also contribute to the observed differences.…”

Section: Discussionmentioning

confidence: 98%

The association between levels of brain‐derived neurotrophic factor and comorbid depression in patients with cardiovascular disease: The Framingham Heart Study

Medved,

Salinas,

Kojis

et al. 2024

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

“…The term S100B refers to a protein identified in the mid-1960s from brain extracts that is characterized by solubility in a 100% saturated solution with ammonium sulfate [ 98 ]. S100B is used as a biomarker of brain damage [ 99 , 100 ], mechanical brain injury, traumatic brain injury induced by alcoholic intoxication, and long-term chemical external impacts (prolonged consumption of ethanol or other psychoactive addictive substances), as well as complex biochemical degenerative processes (associated with Parkinson and Alzheimer’s diseases) [ 101 ]. Khandare et al revealed a correlation of S100B levels (along with neuron-specific enolase protein) with the severity of the infract in ischemic stroke, pointing to S100B as a predictive marker protein for the assessment of how strong the ischemic strike is and what clinical prognosis may be expected.…”

Section: Resultsmentioning

confidence: 99%

Alterations in Neurotrophins in Alcohol-Addicted Patients during Alcohol Withdrawal

Malewska-Kasprzak,

Skibińska,

Dmitrzak-Węglarz

2024

Brain Sciences

View full text Add to dashboard Cite

Background: Alcohol use disorder (AUD) is related to mental and somatic disorders that result in alcohol withdrawal syndrome (AWS), with 30% of AWS cases leading to life-threatening delirium tremens (DTs). Currently, studies do not support using any one biomarker in DTs. Neurotrophins affect neuromodulation, playing a role in the pathogenesis of AUD, AWS, and DTs. Methods: This review aims to summarize experimental and clinical data related to neurotrophins and S100B in neuroplasticity, as well as neurodegeneration in the context of AUD, AWS, and DTs. This work used publications that were selected based on the protocol consistent with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Results: The BDNF level could be a good candidate biomarker for relapse susceptibility, as it is significantly reduced during consumption and gradually increases during abstinence. GDNF influences AUD through its integral role in the function of dopaminergic neurons and ablates the return to alcohol-drinking behavior. NGF protects neurons from ethanol-induced cytotoxic damage and affects recovery from cognitive deficits after brain damage. The NT-3 level is decreased after alcohol exposure and is involved in compensatory mechanisms for cognitive decline in AUD. NT-4 affects oxidative stress, which is associated with chronic alcohol consumption. S100B is used as a biomarker of brain damage, with elevated levels in serum in AUD, and can protect 5-HT neurons from the damage caused by alcohol. Conclusions: BDNF, GDNF, NT-3, NT-4, NGF, and S100B may be valuable markers for withdrawal syndrome. In particular, the most relevant is their association with the development of delirium complications. However, there are few data concerning some neurotrophins in AWS and DTs, suggesting the need for further research.

show abstract